In this week's Stansberry Investor Hour, Dan welcomes value investor Tobias Carlisle back to the show. Tobias is the founder and portfolio manager of Acquirers Funds, a deep-value investment firm. He's also the host of a podcast and the author of numerous books, including The Acquirer's Multiple.

Tobias kicks things off by discussing the performance of his energy fund and the energy sector. He likes to compare gold with oil to see how their pricing has moved in relation to each other over the past year. He thinks oil companies are still cheap and believes that we haven't seen "peak oil" prices yet. He also gives the tickers of two energy companies that he's confident are good places to put your money to take advantage of the energy crisis. (0:00)

Next, Tobias shares two other energy stocks that he's fond of. While these companies aren't as stable as the previous two due to their locations, they possess quality shale sites that make them compelling considerations. Tobias then shifts his attention to two other companies focused on the fertilizer and copper industries. With the first company, he emphasizes that folks need to eat and that the company will aid in food production and remain strong, especially since "nitrogen-based fertilizer feeds half the world." And with the second company, he believes that we're currently in the middle of a cycle for copper demand. (14:52)

Finally, Tobias gives his thoughts on the housing sector. While many investors might avoid it because housing sales are lower than they were at the bottom of the great financial crisis (due to high home prices), he believes that buying now and holding on will pay off when it springs back to life. He also makes the case that in most markets you want to be a contrarian because you can buy good companies at low price-to-earnings multiples. And he cautions investors not to think about companies as blank tickers but as functioning, moving entities that have work put into them that can break them out of stagnancy. (28:34)

In this week's Stansberry Investor Hour, Dan welcomes Michelle Leder back to the show. Michelle is the creator of footnoted.com, an information service dedicated to finding opportunities and early warning signals buried in U.S. Securities and Exchange Commission ("SEC") filings.

Michelle kicks things off by explaining what company proxy statements are and why they matter for investors. She says the summary compensation table and footnotes found in these documents let you know not only how much management is being paid but also what motivates their actions. Michelle emphasizes that as an investor, you need to know whether the company has your best interests in mind. She also says to look at director pay, as some officers sit on the boards of multiple companies and may not be likely to "rock the boat" and push for change. Another key component to examine is the related-party transactions that show you any disclosures in company spending. (0:00)

Next, Michelle says that observing who the owners and top investors are is critical. You should also know how many shares investors have. She says knowing this will let you know if they "have any skin in the game" and will work to ensure that shareholders are being considered. Another aspect to look at is shareholder proposals. Michelle states that there's an argument to be made that proposals should come from shareholders with substantial positions rather than those with smaller stakes. And she gives her thoughts on AI utilization in SEC filings. (19:17)

Finally, Michelle shares one stock that she warned her subscribers about before it fell dramatically over the past year. While some had believed that the stock would perform well, Michelle says the SEC filings were the key indicator to stay away from the company. She also addresses other small details that she looks for to evaluate a company's health and her strategy for short-term signals. (40:25)

In this week's Stansberry Investor Hour, Dan welcomes David Cervantes back to the show. David is the founder of Pinebrook Capital Management – a boutique asset manager focused on asset allocation and managing various systematic trading strategies.

David kicks things off by reflecting on the progress that glucagon-like peptide-1 (GLP-1) drugs have made since his last discussion at a Stansberry Research Conference several years ago. The drug has branched out of medical use into professional use and for standard weight loss, resulting in the companies he previously discussed to have performed well since then. He then discusses the current market shift from the Magnificent Seven to industrials and the S&P 493. The equal-weighted S&P 500, in particular, is beginning to outperform the Mag Seven. And David shares his thoughts on Blue Owl Capital selling its assets and what that means for the private-equity industry. (0:00)

Next, David explains where the money flowing from the Blue Owl sale is coming from and how it's connected to the banking system. If the sell-off negatively impacts banks (and by extension, the labor market comprised of voters), politicians will step in to "fix" things using whatever means necessary. David then gives his thoughts on the U.S. dollar and why he thinks that, despite skepticism and bearish outlooks, it still has what it needs to maintain its current position. And he lists how small-cap stocks have changed in how they operate and their relationship with private equity. (20:44)

Finally, David expresses why the labor market is important for the economy and for policy. Discussions he has had with experts indicate that tightening or hardening the labor market will likely result in layoffs and inflation. Following this, David details the areas that he thinks will do well, given the current market rotation and uncertainty in Iran. (41:52)

In this week's Stansberry Investor Hour, Dan welcomes Cullen Roche back to the show. Cullen is the founder of portfolio-management firm Discipline Funds. He is also the author of several books, his most recent one titled Your Perfect Portfolio.

Cullen kicks things off with his thoughts on market uncertainty due to the Middle East conflict. He believes that volatile oil prices (and other commodities) will have an impact on the market. Additionally, he says that the U.S.'s attacks could prompt an escalating confrontation with China – where the latter decides to invade Taiwan and seize control of Taiwan Semiconductor Manufacturing (TSM), the world's largest semiconductor producer. And he expresses his desire to see a freer market unhindered by tariffs. (0:00)

Next, Cullen delves deep into AI and how it relates to his investing strategies. He states the risk that the technology poses with many companies and sectors pouring money into it. However, he doesn't see that outcome playing out. He then shares how AI has been beneficial for him and says that utilizing it in creative ways can help differentiate your business from the competition. And he gives his outlook on robotics and how that will impact jobs in the future. (20:33)

Finally, Cullen details his exchange-traded funds ("ETFs") and what their purposes are. He also shares the time horizons for the ETFs so investors can know how to plan their strategies over those periods. But Cullen does allow flexibility with his funds to ensure that they can evolve and shift to match the changes in the markets and decrease risk. And he compares the pros and cons of using equal-weighted indexes versus market-cap-weighted indexes. (40:00)

In this week's Stansberry Investor Hour, Dan welcomes Greg Diamond back to the show. Greg is the editor of Ten Stock Trader, an advisory focused on trading using market analysis to find the best opportunities based on previous market patterns.

Greg kicks things off by sharing his theme for 2026: time. He looked at the inflection points in January and is looking at the upcoming ones in April and May. January saw both technology and financial stocks peak before declining. And while Greg believes these sectors are oversold and will correct themselves slightly, the decline will continue. He says that AI taking over is part of this trend, and unlike other "creative destruction" (like the transition from horse-drawn carriages to automobiles) trends in the past, this one is developing much faster. Greg says looking at time cycles and understanding them is essential to prepare for where the market could be heading next. (0:00)

Next, Greg discusses his thoughts on various commodities. He recently traded several positions in silver for wins before the metal's crash and is currently watching to see where it goes from here. He's not as optimistic on oil and natural gas due to the lack of information that investors have outside of OPEC, but he is looking for breakthroughs that could have an impact on the wider market. Copper is another resource that he's interested in, and there are several plays that he believes folks can make. But he says understanding what fuels these movements is more important than why they're occurring. (14:47)

Finally, Greg lists his current trades and where he thinks market volatility is heading. He can't delve too deeply to be fair to his subscribers, but he's preparing to be extremely aggressive in his trades over the next few months. Greg then states that he does his best trading when he ignores what everyone else is saying. He'd rather focus on his monitors and charts than allow himself to be persuaded by outside voices. (31:20)

In this week's Stansberry Investor Hour, Dan welcomes Steve Burns to the show. Steve is the founder of New Trader U, a blog with thousands of articles plus online courses.

Steve kicks things off by explaining how trading is math, detailing how its different components are formulaic. He says that understanding the "math" of expectancy for your returns can help you with managing your discipline, and knowing the risk-to-reward ratio for any trade is the first important step that every investor needs to take before they enter a trade. Steve notes that despite what many folks might believe, being right 50% of the time is pretty good. But even performing that well requires understanding the risks that your trades have. (0:00)

Next, Steve reflects on his early trading days, comparing his methodology and results then with his current strategies. Then he details one metric that determines profitability. It's the most important thing you need to be mindful of that will impact the profits your trades bring in, regardless of factors like win rates. And Steve analyzes the cons with modern trading that ease of entry has provided. Most individual investors don't realize these risks exist and stand poised to lose big. (14:37)

Finally, Steve discusses how to create an edge in trading as an individual investor despite the overwhelming odds. He then explains "positive expectancy," a mathematical formula that shows your average losses versus your average wins. Knowing this can help you more properly filter out volatility, which traders should keep in mind when establishing their position sizes and stop losses. And Steve shares the green lights he looks for when entering a trade. (30:53)

In this week's Stansberry Investor Hour, Dan and Corey welcome Andy Swan to the show. Andy is the co-founder of LikeFolio, a financial-technology company focused on providing its clients with actionable research based on consumer-driven data. He has a free report focused on a new wave of health care and AI that can inform investors of how to best prepare before it arrives. You can download the report here.

Andy kicks things off by sharing how LikeFolio evolved from being designed to create "like" portfolios for social media users based on the companies they and their friends are interested in to being geared toward investors and traders. He says that the data from social media and other publicly available sources is very powerful because it can show where consumer sentiment is for a product and can help estimate sales for a product before an earnings report is released. Andy then provides some of his background in trading, along with his rules for investing.

Next, Andy states that investors need to have some guardrails in place to protect their capital when investing. However, he believes that there's no "one size fits all" method and that investors need to ensure that the rules they establish match their approach. Andy switches the topic to the ease and accessibility of trading with apps like Robinhood. But he warns users to beware leveraged exchange-traded funds – while they sound appealing because of the potential to triple gains, "poisonous" stocks in a fund could send you tumbling. He then gives his thoughts on how AI is changing the world and what he thinks is the next step in its development.

Finally, Andy discusses how one company is currently hated due to its financials, but according to his data, consumers are gravitating toward it. He compares it with other stocks that lost money early on but turned into behemoths in today's market due to new customers consistently using their products. This company could follow in their steps based on his data. And Andy provides his thoughts on the type of mentality to have as an investor.

In this week's Stansberry Investor Hour, Dan and John Engel welcome Dave Lashmet to the show. Dave is the editor of Stansberry Venture Technology, an advisory that takes a "venture capitalist" look at the market. Dave scours the market looking for little-known small-cap companies that are potentially producing the next wonder drug or technology.

Dave kicks things off by discussing the first of three biopharmaceutical companies he's sharing that have monopolies in weight-loss drugs. He starts by showing how drugs gain their monopolies via patents, giving them "economic exclusivity." While companies might be targeting the same patients, the patents influence how they're being treated. The first company gains an edge by not only targeting folks suffering from obesity, but also by treating those with Type 2 diabetes. Dave also explains the contrast in mentality between the U.S. and other countries regarding obesity being preventable. And he provides info showing how obesity is a "slippery slope" and shares that a study found that participants who got off the drug gained back the weight they lost before. (0:00)

Next, Dave sums up how the first company has cleared all of the risks and expenses from clinical trials, while a close competitor still has to get past its trials due to unknown side effects. When asked about why folks would stay on a weight-loss pill for life, Dave points to how our culture has drastically changed over the years, from actively working on farms to passively working in cubicles. These drugs help balance out the resulting shift. Dave then transitions into the next company that has a drug that focuses on fatty liver disease. He explains how this distinction helps the company gain its monopoly due to how irreplaceable livers are. And similar to the first company, this drug will have lifelong consumers. And the good news for investors is that its only competitor causes weight gain. (21:49)

Finally, Dave presents the final company that tackles weight loss by focusing on genetics. Unlike the first two companies, this one treats patients with an injectable drug rather than a pill. However, it zeroes in on our natural "hunger switch," suppressing the users' appetites. Right now, the company is only waiting to get past trials, which puts it at a disadvantage compared with the other two. But Dave still believes that because of how it works, it's still set to stand beside the two pills. (39:44)